Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

NCT06113913 is registered in ClinicalTrials.gov with Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW as lead sponsor.

NCT NCT06113913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06113913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Subcutaneous Infliximab After A Previous Intravenous Dose Optimization
Lead sponsor
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Phase
Phase 4
Overall status
Recruiting
Start date
April 9, 2024
Completion date
November 30, 2026
Enrollment
275 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, inflammatory bowel diseases, ulcerative colitis